Clinical Research Directory

Inclusion Criteria: 1. Male or female aged 18-70 years 2. Diagnosis of AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT 3. Has an HLA-matched related (MRD), HLA-matched unrelated (MUD), haploidentical (HAPLO) or 1-Ag mismatched unrelated donor (MMUD) 4. Karnofsky performance \>70% 5. Adequate major organ system function as demonstrated by: 1. Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockroft-Gault formula). 2. Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT or AST equal or less than 200 IU/ml for adults. Conjugated (direct) bilirubin less than 2x upper limit of normal. 3. Left ventricular ejection fraction equal or greater than 40%. 4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for hemoglobin. 6. Ability to understand and the willingness to sign a written informed consent. a. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial. Exclusion Criteria: 1. Inability to comply with medical recommendations or follow-up 2. Pregnancy 3. Active/uncontrolled bacterial or viral infection (PI is the final arbiter of this criterion.) 4. Has active CNS or ocular disease involvement within 3 months 5. Patients with primary CNS lymphoma 6. Patients who require modifications of the conditional regimen